Search

Your search keyword '"P. Mineur"' showing total 313 results
Start Over Author "P. Mineur"
313 results on '"P. Mineur"'

51. Genetic Mouse Models of Alzheimer's Disease

Author

Yann S. Mineur, Declan McLoughlin, Wim E. Crusio, and Frans Sluyter

Subjects
Neurosciences. Biological psychiatry. Neuropsychiatry, RC321-571
Abstract

In the current minireview, we focus on genetic mouse models of Alzheimer's disease (AD). Because various excellent, up-to-date reviews, special issues, and reliable websites are already dedicated to the genetics of Alzheimer's disease in general and of animal models in particular, this review is not meant to be comprehensive. Rather, we aim to steer the Alzheimer's novice through the recent mouse literature on AD. Special attention will be paid to genetic models that have been tested behaviorally.

Published
2005
Full Text
View/download PDF

52. Genetic Dissection of Learning and Memory in Mice

Author

Yann S. Mineur, Wim E. Crusio, and Frans Sluyter

Subjects
Neurosciences. Biological psychiatry. Neuropsychiatry, RC321-571
Abstract

In this minireview, we discuss different strategies to dissect genetically the keystones of learning and memory. First, we broadly sketch the neurogenetic analysis of complex traits in mice. We then discuss two general strategies to find genes affecting learning and memory: candidate gene studies and whole genome searches. Next, we briefly review more recently developed techniques, such as microarrays and RNA interference. In addition, we focus on gene-environment interactions and endophenotypes. All sections are illustrated with examples from the learning and memory field, including a table summarizing the latest information about genes that have been shown to have effects on learning and memory.

Published
2004
Full Text
View/download PDF

53. COVID-19, impact on myeloma patients

Author

P. Mineur, Caroline Jacquy, Karel Fostier, Juliette Raedemaeker, Géraldine Verstraete, Alain Kentos, Pauline Storms, Ann Van de Velde, Fabio Andreozzi, Sarah Bailly, Florence Van Obbergh, Deborah Bauwens, Marie Lejeune, Michel Delforge, Jasmine Nguyen, Inès Dufour, Anne De Weweire, Nathalie Meuleman, and Marie-Christiane Vekemans

Subjects
Male, medicine.medical_specialty, 2019-20 coronavirus outbreak, Coronavirus disease 2019 (COVID-19), Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Pneumonia, Viral, Betacoronavirus, Belgium, Surveys and Questionnaires, Internal medicine, Pandemic, medicine, Humans, Pandemics, Letter to the Editor, Aged, Aged, 80 and over, Hematology, biology, SARS-CoV-2, Viral Epidemiology, business.industry, COVID-19, General Medicine, Middle Aged, medicine.disease, biology.organism_classification, Virology, Pneumonia, Female, Human medicine, Coronavirus Infections, Multiple Myeloma, business
Published
2020

54. Neoadjuvant chemoradiotherapy with radiation dose escalation with contact x-ray brachytherapy boost or external beam radiotherapy boost for organ preservation in early cT2–cT3 rectal adenocarcinoma (OPERA): a phase 3, randomised controlled trial

Author

Gerard, Jean-Pierre, Barbet, Nicolas, Schiappa, Renaud, Magné, Nicolas, Martel, Isabelle, Mineur, Laurent, Deberne, Mélanie, Zilli, Thomas, Dhadda, Amandeep, and Myint, Arthur Sun

Abstract

Organ preservation after reaching clinical complete response on neoadjuvant therapy is gaining interest for rectal cancers, although the role of radiation dose escalation is still not known. We aimed to determine whether a contact x-ray brachytherapy boost, following or preceding neoadjuvant chemoradiotherapy, increases the probability of 3-year organ preservation for patients with early rectal cancers.

Published
2023
Full Text
View/download PDF

60. Recommendations on the management of multiple myeloma in 2020

Author

Jo Caers, P. Mineur, Chantal Doyen, Marie Christiane Vekemans, Kalung Wu, Nathalie Meuleman, Lucienne Michaux, Michel Delforge, and Alain Kentos

Subjects
Oncology, 2019-20 coronavirus outbreak, medicine.medical_specialty, business.industry, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), medicine.medical_treatment, Disease, Immunotherapy, General Medicine, medicine.disease, Transplantation, 03 medical and health sciences, 0302 clinical medicine, Novel agents, 030220 oncology & carcinogenesis, Daily practice, Internal medicine, hemic and lymphatic diseases, medicine, Humans, 030212 general & internal medicine, business, Multiple Myeloma, Multiple myeloma
Abstract

With the introduction of immunomodulatory drugs, proteasome inhibitors, and anti-CD38 monoclonal antibodies, major improvements have been achieved in the treatment of multiple myeloma (MM), with a significant impact on the outcome of this disease. Different treatment combinations are now in use and other therapies are being developed. Based on an extensive review of the recent literature, we propose practical recommendations on myeloma management, to be used by hematologists as a reference for daily practice.

Published
2020
Full Text
View/download PDF

63. Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study

Author

Verstovsek, Srdan, Gerds, Aaron T, Vannucchi, Alessandro M, Al-Ali, Haifa Kathrin, Lavie, David, Kuykendall, Andrew T, Grosicki, Sebastian, Iurlo, Alessandra, Goh, Yeow Tee, Lazaroiu, Mihaela C, Egyed, Miklos, Fox, Maria Laura, McLornan, Donal, Perkins, Andrew, Yoon, Sung-Soo, Gupta, Vikas, Kiladjian, Jean-Jacques, Granacher, Nikki, Lee, Sung-Eun, Ocroteala, Luminita, Passamonti, Francesco, Harrison, Claire N, Klencke, Barbara J, Ro, Sunhee, Donahue, Rafe, Kawashima, Jun, Mesa, Ruben, Abulafia, Adi Shacham, Al-Ali, Haifa Kathrin, Andreasson, Bjorn, Angona, Anna, Ayala, Rosa, Bang, Soo-Mee, Bank, Bruce, Barraco, Fiorenza, Beggiato, Eloise, Benghiat, Fleur Samantha, Bonifacio, MassimiliaNo, Bories, Claire, Borsaru, Gabriela, Brabrand, Mette, Braester, Andrei, Broliden, Andes, Buxhofer-Ausch, Veronika, Cambier, Nathalie, Caramella, Marianna, Carpentier, Benjamin, Cascavilla, Nicola, Castellano, Maria Giraldo, Chang, Hung, Chen, Chih-Cheng, Cheong, June-Won, Choi, Yunsuk, Choi, Philip, Corsetti, Maria Teresa, Cuadrado, Isabel Montero, Cunningham, Julia, Damaj, Gandhi Laurent, De Stefano, Valerio, Delage, Robert, Delgado, Regina Garcĺa, Diaz, Jose Miguel Torregrosa, Dombi, Péter, Dubruille, Viviane, Egyed, Miklós, El Fassi, Daniel, Elinder-Camburn, Anna, Elli, Elena Maria, Ellis, Martin, Fava, Carmen, Fazal, Salman, Fleischman, Angela, Foltz, Lynda, Fox, Laura, Gabrail, Nashat, Garcĺa-Gutiérrez, Jose Valentĺn, Gerds, Aaron, Girault, Stephane, Gisslinger, Heinz, Gluvacov, Alexandru, Goh, Yeow Tee, Göthert, Joachim, Granacher, Nikki, Grosicki, Sebastian, Gupta, Vikas, Hadjiev (Hadzhiev), Evgeni (Evgueniy), Hafraoui, Kaoutar, Hamed, Aryan, Harrison, Claire, Hasselbalch, Hans, Hauser, Hanns, Heaney, Mark, Hebart, Holger, Hernandez Rivas, Jesus Maria, Higuero Saavedra, Victor, Hillis, Christopher, Hou, Hsin-An, How, Jonathan, Huang, Daniel, Hus, Marek, Illés, Arpad, Isidori, Alessandro, Iurlo, Alessandra, Ivanov, Vadim, Johansson, Peter, Jung, Chul Won, Kiladjian, Jean-Jacques, Kirgner, Ilya, Koren-Michowitz, Maya, Koschmieder, Steffen, Kosztolanyi, Szabolcs Ors, Kreiniz, Natalia, Kuykendall, Andrew, Lambert, Jonathan, Laribi, Kamel, Lascaux, Axelle, Lavie, Noa, Lavie, David, Lazaroiu, Mihaela, Leahy, Michael, Lech-Maranda, Ewa, Lee, Sung-Eun, Lee, Won Sik, Legrand, Ollivier, Lemoli, Roberto, Liang, James, Lim, Sung-Nam, Loschi, Michael, Lucchesi, Alessandro, Macarie, Ioan, Marolleau, Jean-Pierre, Martelli, Maurizio, Mayer, Jiri, McCloskey, James, McDermott, Christopher, McLornan, Donal, McMahon, Brandon, Mehta, Priyanka, Mesa, Ruben, Mikala, Gábor, Milojkovic, Dragana, Mineur, Philippe, Mishchenko, Elena, Moon, Joon Ho, Nagy, Zsolt, Narayanan, Srinivasan, O'Connell, Casey, Ocroteala, Luminita, Oh, Stephen, Ojeda-Uribe, Mario, Ong, Kiat Hoe, Otegbeye, Folashade, Palmer, Jeanne, Pane, Fabrizio, Passamonti, Francesco, Patriarca, Andrea, Perkins, Andrew, Pietrantuono, Giuseppe, Plander, Mark, Platzbecker, Uwe, Prasad, Ritam, Prejzner, Witold, Rachow, Tobias, Radinoff, Atanas, Rejtő, László, Rinaldi, Ciro, Robak, Tadeusz, Rodriguez, Maria Angeles Fernandez, Ronson, Aaron, Ross, David, Sacha, Tomasz, Sadjadian, Parvis, Salar, Antonio, Santillana, Guillermo Sanz, Scheid, Christof, Schmidt, Aline, Severinsen, Marianne Tang, Stoeva, Vera, Szwedyk, Paweł, Tiribelli, Mario, Trautmann-Grill, Karolin, Trottier, Amy, Tzvetkov, Nikolay, van Droogenbroeck, Janusz, Vannucchi, Alessandro, Verstovsek, Srdan, Vianelli, Nicola, von Bubnoff, Nikolas, Wolf, Dominik, Woszczyk, Dariusz, Woźny, Tomasz, Wróbel, Tomasz, Xicoy, Blanca, Yeh, Su-Peng, and Yoon, Sung-Soo

Abstract

Janus kinase (JAK) inhibitors approved for myelofibrosis provide spleen and symptom improvements but do not meaningfully improve anaemia. Momelotinib, a first-in-class inhibitor of activin A receptor type 1 as well as JAK1 and JAK2, has shown symptom, spleen, and anaemia benefits in myelofibrosis. We aimed to confirm the differentiated clinical benefits of momelotinib versus the active comparator danazol in JAK-inhibitor-exposed, symptomatic patients with anaemia and intermediate-risk or high-risk myelofibrosis.

Published
2023
Full Text
View/download PDF

64. Improving transferability of introduced species' distribution models: new tools to forecast the spread of a highly invasive seaweed.

Author

Heroen Verbruggen, Lennert Tyberghein, Gareth S Belton, Frederic Mineur, Alexander Jueterbock, Galice Hoarau, C Frederico D Gurgel, and Olivier De Clerck

Subjects
Medicine, Science
Abstract

The utility of species distribution models for applications in invasion and global change biology is critically dependent on their transferability between regions or points in time, respectively. We introduce two methods that aim to improve the transferability of presence-only models: density-based occurrence thinning and performance-based predictor selection. We evaluate the effect of these methods along with the impact of the choice of model complexity and geographic background on the transferability of a species distribution model between geographic regions. Our multifactorial experiment focuses on the notorious invasive seaweed Caulerpa cylindracea (previously Caulerpa racemosa var. cylindracea) and uses Maxent, a commonly used presence-only modeling technique. We show that model transferability is markedly improved by appropriate predictor selection, with occurrence thinning, model complexity and background choice having relatively minor effects. The data shows that, if available, occurrence records from the native and invaded regions should be combined as this leads to models with high predictive power while reducing the sensitivity to choices made in the modeling process. The inferred distribution model of Caulerpa cylindracea shows the potential for this species to further spread along the coasts of Western Europe, western Africa and the south coast of Australia.

Published
2013
Full Text
View/download PDF

71. AMD3100 disrupts the cross-talk between chronic lymphocytic leukemia cells and a mesenchymal stromal or nurse-like cell-based microenvironment: pre-clinical evidence for its association with chronic lymphocytic leukemia treatments

Author

Basile Stamatopoulos, Nathalie Meuleman, Cécile De Bruyn, Karlien Pieters, Philippe Mineur, Christine Le Roy, Stéphane Saint-Georges, Nadine Varin-Blank, Florence Cymbalista, Dominique Bron, and Laurence Lagneaux

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5
Abstract

Background Interactions with the microenvironment, such as bone marrow mesenchymal stromal cells and nurse-like cells, protect chronic lymphocytic leukemia cells from spontaneous and drug-induced apoptosis. This protection is partially mediated by the chemokine SDF-1α (CXCL12) and its receptor CXCR4 (CD184) present on the chronic lymphocytic leukemia cell surface.Design and Methods Here, we investigated the ability of AMD3100, a CXCR4 antagonist, to sensitize chronic lymphocytic leukemia cells to chemotherapy in a chronic lymphocytic leukemia/mesenchymal stromal cell based or nurse-like cell based microenvironment co-culture model.Results AMD3100 decreased CXCR4 expression signal (n=15, P=0.0078) and inhibited actin polymerization/migration in response to SDF-1α (n=8, P

Published
2012
Full Text
View/download PDF

75. P-162: Compass: a prospective study comparing clinical evaluation with different geriatric screening methods in newly diagnosed elderly multiple myeloma patients

Author

Stef Meers, P. Mineur, Isabelle Vande Broek, Koen Van Eygen, Melanie Vaes, Philip Vlummens, Michel Delforge, Ellen Hoornaert, Cindy Kenis, Ka Lung Wu, Hilde Demuynck, Alain Kentos, Karel Fostier, Natalie Put, Jolien Raddoux, Géraldine Claes, Julien Depaus, Nathalie Meuleman, Anneleen Vanhellemont, Jo Caers, Vincent Maertens, and Ann Van de Velde

Subjects
Cancer Research, medicine.medical_specialty, Geriatric screening, business.industry, Hematology, Newly diagnosed, medicine.disease, Oncology, Internal medicine, Compass, medicine, business, Prospective cohort study, Clinical evaluation, Multiple myeloma
Published
2021

76. Phase III randomized trial comparing systemic versus intra-arterial oxaliplatin, combined with LV5FU2 +/- irinotecan and a targeted therapy, in the first-line treatment of metastatic colorectal cancer restricted to the liver (OSCAR): PRODIGE 49.

Author

Pernot, Simon, Pellerin, Olivier, Mineur, Laurent, Monterymard, Carole, Smith, Denis, Lapuyade, Bruno, Gallois, Claire, Khemissa Akouz, Faiza, De Baere, Thierry, Tougeron, David, Thirot-Bidault, Anne, Audemar, Franck, Simon, Mireille, Lecaille, Cedric, Louafi, Sami, Lepage, Come, Ducreux, Michel, and Taieb, Julien

Abstract

In patients with unresectable liver metastases from colorectal cancer (CRCLM), systemic doublet or triplet chemotherapy and targeted therapy is considered a standard first-line treatment. Hepatic arterial infusion of oxaliplatin (HAI-ox) generates a high response rate, but this still needs to be confirmed in a randomized trial. We incorporated HAI-ox in doublet or triplet + targeted therapy to validate its efficacy. The OSCAR study is an ongoing randomized phase III trial comparing FOLFOX + targeted therapy according to RAS status, or FOLFOXIRI + bevacizumab in patients eligible for triplet therapy, with the same regimen but with HAI-ox instead of IV-ox as the first-line treatment for CRCLM. Main eligibility criteria are colorectal cancer, unresectable liver metastasis, no extra-hepatic metastases except pulmonary nodules if ≤3 and <10 mm, ECOG performance status 0 or 1. The primary endpoint is progression-free survival (PFS). A difference of 4 months for the median PFS in favor of HAI-ox is expected (HR = 0.73). Secondary endpoints include overall survival, overall response rate, secondary liver resection, safety, and quality of life. This study is planned to include 348 patients to demonstrate the superiority of HAI-ox over systemic oxaliplatin in first-line CRCLM treatment (NCT02885753). [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

81. Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial

Author

Dimopoulos, Meletios A, Richardson, Paul G, Bahlis, Nizar J, Grosicki, Sebastian, Cavo, Michele, Beksaç, Meral, Legieć, Wojciech, Liberati, Anna M, Goldschmidt, Hartmut, Belch, Andrew, Magen, Hila, Larocca, Alessandra, Laubach, Jacob P, Petrucci, Maria T, Reece, Donna, White, Darrell, Mateos, María-Victoria, Špička, Ivan, Lazaroiu, Mihaela, Berdeja, Jesús, Kaufman, Jonathan L, Jou, Ying-Ming, Ganetsky, Alex, Popa McKiver, Mihaela, Lonial, Sagar, Weisel, Katja, Dimopoulos, Meletios A, Richardson, Paul G, Bahlis, Nizar J, Grosicki, Sebastian, Cavo, Michele, Beksaç, Meral, Legieć, Wojciech, Liberati, Anna M, Goldschmidt, Hartmut, Belch, Andrew, Magen, Hila, Larocca, Alessandra, Laubach, Jacob P, Petrucci, Maria T, Reece, Donna, White, Darrell, Mateos, María-Victoria, Špička, Ivan, Lazaroiu, Mihaela, Berdeja, Jesús, Kaufman, Jonathan L, Jou, Ying-Ming, Ganetsky, Alex, Popa McKiver, Mihaela, Lonial, Sagar, Weisel, Katja, Sandhu, Irwindeep, Podhorecka, Monika, Palumbo, Antonio, Shacham-Abulafia, Adi, Vaxman, Iuliana, Shpilberg, Ofer, Besemer, Britta, Martelli, Maurizio, Foà, Roberto, De Fabritiis, Paolo, Caravita di Toritto, Tommaso, Gheorghita, Emanuil, Oriol, Albert, Rowlings, Philip, Emanuele, Angelucci, Carella, Angelo M, Offidani, Massimo, Bladé, Joan, Casado, Luis F, Oakervee, Heather, Panelli, Victoria, Meza, Luis, Kühr, Thomas, Granell, Miguel, Benson, Don, Nair, Rajesh, Holden, Viran, Reeves, James, Eek, Richard W, Walker, Patricia A, Catalano, John, Rosta, András, Lech-Marańda, Ewa, Samaras, Christy, Reiman, Anthony, Weaver, Robert, Acs, Peter, Grigg, Andrew, De Prijck, Bernard, Louzada, Martha, Minuk, Leonard, Sebag, Michael, Klausmann, Martine, Welslau, Manfred, Hellmann, Andrzej, Danaila, Catalin, Becker, Pamela, Bensinger, William, Porterfield, Bruce, Modiano, Manuel, Schultz, Stephen M, Manges, Robert, Lee, Huey-Shin Cindy, Gray, James X, Wright, Matthew P, Vekemans, Marie-Christine, Hamed, Aryan, Gasztonyi, Zoltán, Mikala, Gábor, Masszi, Tamás, Gamberi, Barbara, Kuliczkowski, Kazimierz, Usnarska-Zubkiewicz, Lidia, Bengoechea, Enrique, Gutiérrez, María AE, García, Miguel TH, San-Miguel, Jesús, Driessen, Christoph, Behl, Rajesh, Brenner, Warren, Gray, Carl, Hansen, Vincent, Moezi, Mehdi, Cortes, Hector V, Yen, Charles, Gressot, Laurent, Horvath, Noemi, D'Rozario, James M, Latimer, Maya, Kyrtsonis, Maria-Christine, Chubar, Evgeni, Mittelman, Moshe, Baldini, Luca, Tosi, Patrizia, Vacca, Angelo, Jędrzejczak, Wiesław W, Robak, Tadeusz, Lahuerta, Juan J, Carney, Jennifer, Chen, Franklin, Hirsch, Robert, Ruiz, Marco, Alencar, Alvaro, Jagasia, Madan, Kasbari, Samer, Kuriakose, Philip, Mahmood, Aftab, Chaudhry, Madhu, Cohen, Gary, Noga, Stephen, Roa, Sch, Jakubowiak, Andrzej, Rosenbaum, Cara, Delforge, Michel, Delrieu, Vanessa, Doyen, Chantal, Dries, Deeren, Demuynck, Hilde, Schots, Rik, Maisnar, Vladimir, Blau, Igor W, Dürk, Heinz A, Kerkhoff, Andrea, Kropff, Martin, Munder, Markus, Röllig, Christoph, Scheid, Christof, Symeonidis, Argiris S, Illés, Árpád, Coyne, Mark, O'Gorman, Peter, Hayden, Patrick, O'Dwyer, Michael, Ben-Yehuda, Dina, Braester, Andrei, Nemets, Anatoly, Lugassy, Gilles, Cohen, Yossi, Rahimi-Levene, Naomi, Bosi, Alberto, Pezzatti, Sara, Rossini, Fausto, Pogliani, Enrico M, Pinto, Antonello, Komarnicki, Mieczysław, Borsaru, Gabriela, Stoia, Razvan, Afanasyev, Boris, Goñi, María A, Carboneras, Ana V, Ali, Sarah, Rubenstein, S. Eric, Caputto, Salvador, Cosgriff, Thomas, Fanning, Suzanne, Khojasteh, Ali, Liman, Andrew, Malcolm, Albert, Vrindavanam, Nandagopal, Patel, Ravindranath, Belani, Rajesh, Shieh, Marie, Stockerl-Goldstein, Keith, Strnad, Charles, Stuart, Robert, Chhabra, Saurabh, Costa, Luciano, Jhangiani, Haresh, Augustson, Bradley, Filshie, Robin, Johnston, Amanda, Hertzberg, Mark S, Mineur, Philippe, Fox, Susan, Kotb, Rami, Dao, Vi, LeBlanc, Richard, Gregora, Evzen, Brioli, Annamaria, Mügge, Lars-Olof, Hänel, Mathias, Langer, Christian, Kapsali, Eleni, Briasoulis, Evangelos, Kyriakou, Despoina, Hardan, Izhar, Horowitz, Netanel A, Clotilde, Cangialosi, Fabbiano, Francesco, Castagnari, Barbara, Ciceri, Fabio, Musuraca, Gerardo, Deptała, Andrzej, Kłoczko, Janusz, Balea, Marius, Vladareanu, Ana-Maria, Rossiev, Victor, Alegre, Adrián, Encinas, Cristina, Gayoso, Jorge, Pabst, Thomas, Rabin, Neil, Arledge, Sherri, Cabanillas, Fernando, Catlett, Joseph, Chidiac, Tarek, Clarkson, David, Dhodapkar, Madhav, Geils, George, Khan, Cyrus MA, Sahovic, Entezam, Khasawneh, Mohamad, Sehgal, Rajesh, Ballester, Oscar, Levy, Moshe, Fay, Joseph, Liem, Kiem, Lunning, Matthew, Vose, Julie, Faber, Edward, MacFarlane, Donald, Hohl, Raymond, Mahmood, Tariq, Bhaskar, Birbal, Mims, Martha, Oliff, Ira, Paner, Agne, Maciejewski, John, Padmanabhan, Arvinda, Richard, Robert, Sanyal, Amit, Schiller, Gary, Staszewski, Harry, Stevens, Don, Vaughn, Christopher, and Windsor, Kevin

Abstract

Elotuzumab plus lenalidomide and dexamethasone has shown improved progression-free and overall survival versus lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma. We aimed to assess these regimens in patients with newly diagnosed multiple myeloma who are ineligible for haematopoietic stem-cell transplantation (HSCT).

Published
2022
Full Text
View/download PDF

82. Diabetes insipidus and acute myeloid leukemia harboring monosomy 7: report of two cases and literature review

Author

P. Mineur, Huu Hanh Lê, Marie Henin, Jean-Philippe Lengelé, and Sébastien Toffoli

Subjects
Chromosome 7 (human), Oncology, medicine.medical_specialty, business.industry, Myeloid leukemia, General Medicine, medicine.disease, 03 medical and health sciences, Leukemia, Myeloid, Acute, 0302 clinical medicine, Chromosome 3, hemic and lymphatic diseases, 030220 oncology & carcinogenesis, Internal medicine, Diabetes insipidus, medicine, Diabetes Mellitus, Humans, In patient, 030212 general & internal medicine, Chromosome Deletion, business, Chromosomes, Human, Pair 7, Diabetes Insipidus
Abstract

Acute myeloid leukemia (AML) is unusually associated with diabetes insipidus (DI) in patients bearing monosomy 7 or chromosome 3 aberrations. To date, 84 cases have been reported worldwide. Physiopathological mechanisms linking these chromosomal abnormalities to DI are not yet understood. We report two patients with AML/DI and review the medical literature on those conditions.

Published
2019

83. Pembrolizumab with Capox Bevacizumab in patients with microsatellite stable metastatic colorectal cancer and a high immune infiltrate: The FFCD 1703-POCHI trial.

Author

Gallois, Claire, Emile, Jean-François, Kim, Stefano, Monterymard, Carole, Gilabert, Marine, Bez, Jérémie, Lièvre, Astrid, Dahan, Laetitia, Laurent-Puig, Pierre, Mineur, Laurent, Coriat, Romain, Legoux, Jean-Louis, Hautefeuille, Vincent, Phelip, Jean-Marc, Lecomte, Thierry, Sokol, Harry, Capron, Claude, Randrian, Violaine, Lepage, Come, and Lomenie, Nicolas

Abstract

Pembrolizumab, a PD1 immune checkpoint inhibitor (ICI), was recently reported to be very effective in patients with microsatellite instable/deficient mismatch repair metastatic colorectal cancer (MSI/dMMR mCRC), unlike patients with microsatellite stable/proficient MMR (MSS/pMMR) mCRC, in whom ICIs are generally ineffective. However, about 15% of MSS/pMMR CRCs are highly infiltrated by tumour infiltrating lymphocytes. In addition, both oxaliplatin and bevacizumab have been shown to have immunomodulatory properties that may increase the efficacy of an ICI. We formulated the hypothesis that patients with MSS/pMMR mCRC with a high immune infiltrate can be sensitive to ICI plus oxalipatin and bevacizumab-based chemotherapy. POCHI is a multicenter, open-label, single-arm phase II trial to evaluate efficacy of Pembrolizumab with Capox Bevacizumab as first-line treatment of MSS/pMMR mCRC with a high immune infiltrate for which we plan to enrol 55 patients. Primary endpoint is progression-free survival (PFS) at 10 months, which is expected greater than 50%, but a 70% rate is hoped for. Main secondary objectives are overall survival, secondary resection rate and depth of response. Patients must have been resected of their primary tumour so as to evaluate two different immune scores (Immunoscore® and TuLIS) and are eligible if one score is "high". The first patient was included on April 20, 2021. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

84. Bortezomib and high-dose melphalan conditioning regimen in frontline multiple myeloma: an IFM randomized phase 3 study

Author

Roussel, Murielle, Lauwers-Cances, Valérie, Macro, Margaret, Leleu, Xavier, Royer, Bruno, Hulin, Cyrille, Karlin, Lionel, Perrot, Aurore, Touzeau, Cyrille, Chrétien, Marie-Lorraine, Rigaudeau, Sophie, Dib, Mamoun, Nicolas-Virelizier, Emmanuelle, Escoffre-Barbe, Martine, Belhadj, Karim, Mariette, Clara, Stoppa, Anne-Marie, Araujo, Carla, Doyen, Chantal, Fontan, Jean, Kolb, Brigitte, Garderet, Laurent, Brechignac, Sabine, Malfuson, Jean-Valère, Jaccard, Arnaud, Lenain, Pascal, Borel, Cécile, Hebraud, Benjamin, Benbrahim, Omar, Dorvaux, Véronique, Manier, Salomon, Augeul-Meunier, Karine, Vekemans, Marie-Christiane, Randriamalala, Edouard, Chaoui, Driss, Caers, Jo, Chaleteix, Carine, Benboubker, Lofti, Vincent, Laure, Glaisner, Sylvie, Zunic, Patricia, Slama, Borhane, Eveillard, Jean-Richard, Humbrecht-Kraut, Catherine, Morel, Véronique, Mineur, Philippe, Eisenmann, Jean-Claude, Demarquette, Hélène, Richez, Valentine, Vignon, Marguerite, Caillot, Denis, Facon, Thierry, Moreau, Philippe, Colin, Anne-Laurène, Olivier, Pascale, Wuilleme, Soraya, Avet-Loiseau, Hervé, Corre, Jill, and Attal, Michel

Abstract

High-dose melphalan (HDM) and transplantation are recommended for eligible patients with multiple myeloma. No other conditioning regimen has proven to be more effective and/or safer. We previously reported in a phase 2 study that bortezomib can safely and effectively be combined with HDM (Bor-HDM), with a 32% complete response (CR) rate after transplantation. These data supported a randomized phase 3 trial. Randomization was stratified according to risk and response to induction: 300 patients were enrolled, and 154 were allocated to the experimental arm (ie, arm A) with bortezomib (1 mg/m2 intravenously [IV]) on days −6, –3, +1, and +4 and melphalan (200 mg/m2 IV) on day –2. The control arm (ie, arm B) consisted of HDM alone (200 mg/m2 IV). There were no differences in stringent CR + CR rates at day 60 posttransplant (primary end point): 22.1% in arm A vs 20.5% in arm B (P = .844). There were also no differences in undetectable minimum residual disease rates: 41.3% vs 39.4% (P = .864). Median progression-free survival was 34.0 months for arm A vs 29.6 months for arm B (adjusted HR, 0.82; 95% CI, 0.61-1.13; P = .244). The estimated 3-year overall survival was 89.5% in both arms (hazard ratio, 1.28; 95% CI, 0.62-2.64; P = .374). Sixty-nine serious adverse events occurred in 18.7% of Bor-HDM–treated patients (vs 13.1% in HDM-treated patients). The proportion of grade 3/4 AEs was similar within the 2 groups (72.0% vs 73.1%), mainly (as expected) blood and gastrointestinal disorders; 4% of patients reported grade 3/4 or painful peripheral neuropathy in arm A (vs 1.5% in arm B). In this randomized phase 3 study, a conditioning regimen with Bor-HDM did not improve efficacy end points or outcomes compared with HDM alone. The original trial was registered at www.clinicaltrials.gov as #NCT02197221.

Published
2022
Full Text
View/download PDF

85. Recommendations on the management of multiple myeloma in 2020

Author

Vekemans, Marie-Christiane, Doyen, Chantal, Caers, Jo, Wu, Kalung, Kentos, Alain, Mineur, Philippe, Michaux, Lucienne, Delforge, Michel, and Meuleman, Nathalie

Abstract

ABSTRACTWith the introduction of immunomodulatory drugs, proteasome inhibitors, and anti-CD38 monoclonal antibodies, major improvements have been achieved in the treatment of multiple myeloma (MM), with a significant impact on the outcome of this disease. Different treatment combinations are now in use and other therapies are being developed. Based on an extensive review of the recent literature, we propose practical recommendations on myeloma management, to be used by hematologists as a reference for daily practice.

Published
2022
Full Text
View/download PDF

86. Skin toxicity and quality of life in patients with metastatic colorectal cancer during first-line panitumumab plus FOLFIRI treatment in a single-arm phase II study

Author

Thaler Josef, Karthaus Meinolf, Mineur Laurent, Greil Richard, Letocha Henry, Hofheinz Ralf, Fernebro Eva, Gamelin Erick, Baños Ana, and Köhne Claus-Henning

Subjects
Colorectal cancer, Panitumumab, Quality of life, Tolerability, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Abstract Background Integument-related toxicities are common during epidermal growth factor receptor (EGFR)-targeted therapy. Panitumumab is a fully human monoclonal antibody targeting the EGFR that significantly improves progression-free survival when added to chemotherapy in patients with metastatic colorectal cancer who have wild-type (WT) KRAS tumours. Primary efficacy and tolerability results from a phase II single-arm study of first-line panitumumab plus FOLFIRI in patients with metastatic colorectal cancer have been reported. Here we report additional descriptive tolerability and quality of life data from this trial. Methods Integument-related toxicities and quality of life were analysed; toxicities were graded using modified National Cancer Institute Common Toxicity Criteria. Kaplan-Meier estimates of time to and duration of first integument-related toxicity were prepared. Quality of life was measured using EuroQoL EQ-5D and EORTC QLQ-C30. Best overall response was analysed by skin toxicity grade and baseline quality of life. Change in quality of life was analysed by skin toxicity severity. Results 154 patients were enrolled (WT KRAS n = 86; mutant KRAS n = 59); most (98%) experienced integument-related toxicities (most commonly rash [42%], dry skin [40%] and acne [36%]). Median time to first integument-related toxicity was 8 days; median duration was 334 days. Overall, proportionally more patients with grade 2+ skin toxicity responded (56%) compared with those with grade 0/1 (29%). Mean overall EQ-5D health state index scores (0.81 vs. 0.78), health rating scores (72.5 vs. 71.0) and QLQ-C30 global health status scores (65.8 vs. 66.7) were comparable at baseline vs. safety follow-up (8 weeks after completion), respectively and appeared unaffected by skin toxicity severity. Conclusions First-line panitumumab plus FOLFIRI has acceptable tolerability and appears to have little impact on quality of life, despite the high incidence of integument-related toxicity. Trial registration ClinicalTrials.gov NCT00508404

Published
2012
Full Text
View/download PDF

87. Gilteritinib activity in refractory or relapsed FLT3-mutated acute myeloid leukemia patients previously treated by intensive chemotherapy and midostaurin: a study from the French AML Intergroup ALFA/FILO

Author

Dumas, Pierre-Yves, Raffoux, Emmanuel, Bérard, Emilie, Bertoli, Sarah, Hospital, Marie-Anne, Heiblig, Maël, Desbrosses, Yohann, Bonmati, Caroline, Pautas, Cécile, Lambert, Juliette, Orvain, Corentin, Banos, Anne, Pasquier, Florence, Peterlin, Pierre, Marchand, Tony, Uzunov, Madalina, Frayfer, Jamilé, Turlure, Pascal, Cluzeau, Thomas, Jourdan, Eric, Himberlin, Chantal, Tavernier, Emmanuelle, Villate, Alban, Haiat, Stephanie, Chretien, Marie-Lorraine, Carre, Martin, Chantepie, Sylvain, Vaida, Ioana, Wemeau, Mathieu, Chebrek, Safia, Guillerm, Gaelle, Guièze, Romain, Debarri, Houria, Gehlkopf, Eve, Laribi, Kamel, Marcais, Ambroise, Santagostino, Alberto, Béné, Marie-Christine, Mineur, Ariane, Pigneux, Arnaud, Dombret, Hervé, and Récher, Christian

Abstract

The real-world efficacy and safety of gilteritinib was assessed in an ambispective study that included 167 R/R FLT3-mutated AML patients. Among them, 140 received gilteritinib as single agent (cohort B), including 67 previously treated by intensive chemotherapy and midostaurin (cohort C). The main differences in patient characteristics in this study compared to the ADMIRAL trial were ECOG ≥ 2 (83.6% vs. 16.6%), FLT3-TKD mutation (21.0% vs.8.5%), primary induction failure (15.0% vs.40.0%) and line of treatment (beyond 2nd in 37.1% vs.0.0%). The rates of composite complete remission, excluding those that occurred after hematopoietic stem cell transplantation (HSCT), were similar at respectively 25.4% and 27.5% in cohorts B and C. Median overall survival (OS) for these two groups was also similar at respectively 6.4 and 7.8 months. Multivariate analyses for prognostic factors associated with OS identified female gender (HR 1.61), adverse cytogenetic risk (HR 2.52), and allogenic HSCT after gilteritinib (HR 0.13). Although these patients were more heavily pretreated, these real-world data reproduce the results of ADMIRAL and provide new insights into the course of patients previously treated by intensive chemotherapy and midostaurin and beyond the 2nd line of treatment who can benefit from treatment in an outpatient setting.

Published
2022
Full Text
View/download PDF

88. Opposite Prognostic Significance of Cellular and Serum Circulating MicroRNA-150 in Patients with Chronic Lymphocytic Leukemia

Author

Emerence Crompot, Nathalie Meuleman, Laurence Lagneaux, P. Mineur, Michaël Van Damme, Barbara Dessars, Dominique Bron, Basile Stamatopoulos, and Hakim El Housni

Subjects
Adult, Lymphocytosis, Chronic lymphocytic leukemia, Gene Expression, Exosomes, Recurrence, microRNA, Biomarkers, Tumor, Genetics, medicine, Humans, Molecular Biology, Genetics (clinical), Aged, Aged, 80 and over, business.industry, Case-control study, Articles, Middle Aged, Prognosis, medicine.disease, Leukemia, Lymphocytic, Chronic, B-Cell, Molecular medicine, Pathophysiology, Tumor Burden, MicroRNAs, Circulating MicroRNA, Leukemia, Case-Control Studies, Immunology, Disease Progression, Cancer research, Molecular Medicine, medicine.symptom, business, Follow-Up Studies
Abstract

MicroRNAs (or miRs) play a crucial role in chronic lymphocytic leukemia (CLL) physiopathology and prognosis. In addition, circulating microRNAs in body fluids have been proposed as new biomarkers. We investigated the expression of matched cellular and serum circulating microRNA-150 by quantitative real-time PCR (qPCR) from purified CD19+ cells or from CLL serums obtained at diagnosis in a cohort of 273/252 CLL patients with a median follow-up of 78 months (range 7–380) and correlated it to other biological or clinical parameters. We showed that miR-150 was significantly overexpressed in CLL cells/serums compared with healthy subjects (P < 0.0001). Among CLL patients, a low cellular miR-150 expression level was associated with tumor burden, disease aggressiveness and poor prognostic factors. In contrast, a high level of serum miR-150 was associated with tumor burden markers and some markers of poor prognosis. Similarly, cellular and serum miR-150 also predicted treatment-free survival (TFS) and overall survival (OS) in an opposite manner: patients with low cellular/serum miR-150 levels have median TFS of 40/111 months compared with high-level patients who have a median TFS of 122/60 months (P < 0.0001/P = 0.0066). Similar results were observed for OS. We also found that cellular and serum miR-150 levels vary in an opposite manner during disease progression and that cellular miR-150 could be regulated by its release into the extracellular space. Cellular and serum levels of miR-150 are associated with opposite clinical prognoses and could be used to molecularly monitor disease evolution as a new prognostic factor in CLL.

Published
2015

89. Epag 2015 : A Phase II Randomized Placebo-Controlled Study to Assess the Impact on Outcome of Eltrombopag Administered to Elderly Patients with Acute Myeloid Leukemia Receiving Induction Chemotherapy. a French Innovative Leukemia Organization (FILO) Study

Author

Pigneux, Arnaud, Dumas, Pierre-Yves, Bernard, Marc, Vey, Norbert, Bidet, Audrey, Mineur, Ariane, Hunault, Mathilde, Carre, Martin, Ojeda, Mario, Banos, Anne, Peterlin, Pierre, Guieze, Romain, Desbrosses, Yohan, Roth Guepin, Gabrielle, Simand, Celestine, Leguay, Thibaut, Gyan, Emmanuel, Jourdan, Eric, Vial, Jean-Philippe, Marchand, Tony, Hicheri, Yosr, Bene, Marie C, Hamel, Jean Francois, and Recher, Christian

Published
2022
Full Text
View/download PDF

90. Dexaml-02 : A Phase II Study of Dexamethasone Added to Induction and Postremission Therapy in Older Patients with Newly Diagnosed AML. a French Innovative Leukemia Organization (FILO) Study

Author

Recher, Christian, Bertoli, Sarah, Peterlin, Pierre, Guieze, Romain, Desbrosses, Yohan, Hicheri, Yosr, Benbrahim, Omar, Carre, Martin, Mathilde, Hunault-Berger, Banos, Anne, Bernard, Marc, Gyan, Emmanuel, Saad, Alain, Chebrek, Safia, Roth Guepin, Gabrielle, Dorvaux, Veronique, Sanhes, Laurence, Gallego Hernanz, Maria Pilar, Exbrayat, Carole, Vincent, Laure, Himberlin, Chantal, Largeaud, Laetitia, Delabesse, Eric, Vergez, Francois, Vey, Norbert, Mineur, Ariane C, Simand, Célestine, Luquet, Isabelle, and Pigneux, Arnaud

Published
2022
Full Text
View/download PDF

92. PF694 TREATMENT-FREE REMISSION AFTER TPO RECEPTOR AGONISTS IN ADULT ITP PATIENTS IN BELGIUM

Author

D Selleslag, Christine Schuermans, Dimitri Breems, Vincent Maertens, P. Mineur, A. Van de Velde, Karel Fostier, Melanie Vaes, Dries Deeren, A. Vantilborgh, K. Theunissen, Alain Kentos, L. Schauvliege, Catherine Lambert, André Efira, Mia Janssen, Yves Beguin, Ann Janssens, and K. Van Eygen

Subjects
business.industry, Immunology, Medicine, Hematology, business, Receptor
Published
2019

93. Nal-IRI/LV5-FU versus paclitaxel as second-line therapy in patients with metastatic esophageal squamous cell carcinoma (OESIRI)-PRODIGE 62: A multicentre, randomised, non-comparative phase II study.

Author

Randrian, Violaine, Adenis, Antoine, Desrame, Jérôme, Barbier, Emilie, Di Fiore, Frédéric, Lièvre, Astrid, Dahan, Laetitia, Laurent-Puig, Pierre, Mineur, Laurent, Breysacher, Gilles, Roquin, Guillaume, Louafi, Samy, Lopez, Anthony, Louvet, Christophe, Borg, Christophe, Metges, Jean Philippe, Faroux, Roger, Gaba, Lila, Manfredi, Sylvain, and Tougeron, David

Abstract

Half of patients newly diagnosed with esophageal squamous cell cancer (ESCC) have metastatic disease (mESCC) and therefore a poor prognosis. Furthermore, half of patients with initial loco-regional disease present disease recurrence after surgery and/or chemoradiation. In mESCC, the recommended first-line treatment combines 5-fluorouracil and cisplatin, although this has not been validated by a phase III trial. Patients with disease progression or recurrence after platinum-based chemotherapy and good performance status probably benefit from second-line chemotherapy. Several molecules have been evaluated in phase I/II trials or retrospective studies (docetaxel, paclitaxel and irinotecan) but no randomised studies are available. OESIRI is a multicentre, randomised, open-label phase II trial designed to evaluate efficacy and safety of liposomal irinotecan (nal-IRI) plus 5-FU versus paclitaxel as second-line therapy in patients with mESCC. The main inclusion criteria are histologically proven mESCC in progression after first-line platinum-based chemotherapy. Patients with initial resectable disease can be included if recurrence occurred within 6 months. The primary objective is to evaluate the percentage of patients alive 9 months after randomisation. Secondary endpoints are progression-free survival, overall survival, response rate, safety and quality of life. In addition, circulating tumour DNA will be monitored to assess its prognostic value. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

94. Relations in Chains

Author

Mineur, B. W.

Abstract

The criticisms made against chain indexing are reviewed, and PRECIS briefly considered as a possible (but improbable) general substitute for indexing. The failures of chain indexing arise mainly from an overemphasis on generic relationships. The use of symbols to represent relations between terms is suggested for the chain index. (80 references) (Author/SJ)

Published
1973

95. Lomustine is beneficial to older AML with ELN2017 adverse risk profile and intermediate karyotype: a FILO study

Author

Largeaud, Laetitia, Cornillet-Lefebvre, Pascale, Hamel, Jean-François, Dumas, Pierre-Yves, Prade, Naïs, Dufrechou, Stéphanie, Plenecassagnes, Julien, Luquet, Isabelle, Blanchet, Odile, Banos, Anne, Béné, Marie C., Bernard, Marc, Bertoli, Sarah, Bonmati, Caroline, Fornecker, Luc Matthieu, Guièze, Romain, Haddaoui, Lamya, Hunault, Mathilde, Ianotto, Jean Christophe, Jourdan, Eric, Ojeda, Mario, Peterlin, Pierre, Vey, Norbert, Zerazhi, Hacene, Yosr, Hicheri, Mineur, Ariane, Cahn, Jean-Yves, Ifrah, Norbert, Récher, Christian, Pigneux, Arnaud, and Delabesse, Eric

Abstract

We previously reported the benefit of lomustine addition to conventional chemotherapy in older acute myeloid leukemias with nonadverse chromosomal aberrations in the LAM-SA 2007 randomized clinical trial (NCT00590837). A molecular analysis of 52 genes performed in 330 patients included in this trial, 163 patients being treated with lomustine in combination with idarubicin and cytarabine and 167 without lomustine, identified 1088 mutations with an average of 3.3 mutations per patient. NPM1, FLT3, and DNMT3Awere the most frequently mutated genes. A putative therapeutic target was identified in 178 patients (54%). Among five molecular classifications analyzed, the ELN2017 risk classification has the stronger association with the clinical evolution. Patients not treated with lomustine have an expected survival prognosis in agreement with this classification regarding the overall and event-free survivals. In strong contrast, lomustine erased the ELN2017 classification prognosis. The benefit of lomustine in nonadverse chromosomal aberrations was restricted to patients with RUNX1, ASXL1, TP53, and FLT3-ITDhigh/NPM1WTmutations in contrast to the intermediate and favorable ELN2017 patients. This post-hoc analysis identified a subgroup of fit elderly AML patients with intermediate cytogenetics and molecular markers who may benefit from lomustine addition to intensive chemotherapy.

Published
2021
Full Text
View/download PDF

96. Diabetes insipidus and acute myeloid leukemia harboring monosomy 7: report of two cases and literature review

Author

Lê, Huu Hanh, Lengelé, Jean-Philippe, Henin, Marie, Toffoli, Sébastien, and Mineur, Philippe

Abstract

ABSTRACTAcute myeloid leukemia (AML) is unusually associated with diabetes insipidus (DI) in patients bearing monosomy 7 or chromosome 3 aberrations. To date, 84 cases have been reported worldwide. Physiopathological mechanisms linking these chromosomal abnormalities to DI are not yet understood. We report two patients with AML/DI and review the medical literature on those conditions.

Published
2021
Full Text
View/download PDF

97. Rituximab in auto-immune haemolytic anaemia and immune thrombocytopenic purpura: a Belgian retrospective multicentric study

Author

Daan Dierickx, A. Van Hoof, P-Q Le, A. Roest, Ann Janssens, D Boulet, Gregor Verhoef, Gitte Bries, P. Mineur, Alain Kentos, André Delannoy, Agnes Triffet, and P Pierre

Subjects
Adult, Male, Pediatrics, medicine.medical_specialty, Adolescent, Cold agglutinin disease, medicine.medical_treatment, Splenectomy, Disease-Free Survival, Antibodies, Monoclonal, Murine-Derived, Young Adult, Belgium, immune system diseases, hemic and lymphatic diseases, Immunopathology, Internal Medicine, Humans, Immunologic Factors, Medicine, Progression-free survival, Child, Aged, Retrospective Studies, Aged, 80 and over, Purpura, Thrombocytopenic, Idiopathic, business.industry, Antibodies, Monoclonal, Infant, Retrospective cohort study, Middle Aged, medicine.disease, Thrombocytopenic purpura, Surgery, Treatment Outcome, Child, Preschool, Female, Rituximab, Anemia, Hemolytic, Autoimmune, Autoimmune hemolytic anemia, business, medicine.drug
Abstract

Dierickx D, Verhoef G, Van Hoof A, Mineur P, Roest A, Triffet A, Kentos A, Pierre P, Boulet D, Bries G, Le P-Q, Janssens A, Delannoy A (University Hospital Gasthuisberg, Leuven; Algemeen Ziekenhuis St. Jan, Brugge; Grand Hopital de Charleroi, Gilly; ZNA Stuyvenberg, Antwerpen; Centre Hospitalier Universitaire, Charleroi; ULB Hopital Erasme, Brussels; Cliniques du Sud-Luxembourg, Arlon; CHR Saint Joseph, Mons; Virga Jesseziekenhuis, Hasselt; Children's University Hospital Reine Fabiola, Brussels; and Hopital de Jolimont, Haine-Saint-Paul and Cliniques Universitaires St Luc, Brussels; Belgium). Rituximab in auto-immune haemolytic anaemia and immune thrombocytopenic purpura:a Belgian retrospective multicentric study. J Intern Med 2009;Objectives. For better characterizing the effect of anti-CD20 therapy, we analysed the use of rituximab in Belgian patients experiencing auto-immune haemolytic anaemia (AIHA) and immune thrombocytopenic purpura (ITP). Design. We performed a retrospective multicentric analysis of patients with AIHA and ITP treated with rituximab in Belgium. Setting. Haematological departments were invited to fill in a questionnaire about patient and disease characteristics. Subjects. All patients with AIHA and ITP, both primary and secondary to other diseases, who received one or more courses of rituximab during their disease course were included. Sixty-eight courses of rituximab in 53 patients with AIHA and 43 courses in 40 patients with ITP were analyzed. Intervention. Response rates, duration of response and factors predictive for response were assessed. Results. All patients were given rituximab after failing at least one previous line of treatment, including splenectomy in 19% and 72.5% of AIHA-patients and ITP-patients respectively. Overall response rates were 79.2% in AIHA and 70% in ITP, with a median follow-up since first rituximab administration of 15 months (range 0.5-62) in AIHA and 11 months (range 0-74) in ITP. Progression free survival at 1 and 2 years were 72% and 56% in AIHA and 70% and 44% in ITP. In this retrospective analysis we were not able to identify pretreatment characteristics predictive for response to rituximab. Nine patients with AIHA and three patients with ITP were given one or more additional courses of rituximab. Most of these patients, who had responded to a previous course, experienced a new response comparable to the previous one, both in terms of quality and of duration of response. Finally, the outcome of patients who failed to respond to rituximab therapy was poor both in terms of response to subsequent therapy and in terms of survival. Conclusions. This study confirms that rituximab induces responses in a majority of previously treated patients with AIHA and ITP. Response duration generally exceeds 1 year. Retreatment with rituximab in responding patients is most often successful. The outcome of patients who fail on rituximab is poor. We were not able to identify pretreatment patient characteristics predicting for response. © 2009 Blackwell Publishing Ltd.

Published
2009

99. Does A Longer Waiting Period After Neoadjuvant Radio-chemotherapy Improve the Oncological Prognosis of Rectal Cancer? Three Years' Follow-up Results of the Greccar-6 Randomized Multicenter Trial.

Author

Lefèvre, Jérémie H., Mineur, Laurent, Cachanado, Marine, Denost, Quentin, Rouanet, Philippe, de Chaisemartin, Cécile, Meunier, Bernard, Mehrdad, Jafari, Cotte, Eddy, Desrame, Jérome, Karoui, Mehdi, Benoist, Stéphane, Kirzin, Sylvain, Berger, Anne, Panis, Yves, Piessen, Guillaume, Saudemont, Alain, Prudhomme, Michel, Peschaud, Frédérique, and Dubois, Anne

Abstract

Objective: The aim of this study was to report the 3-year survival results of the GRECCAR-6 trial. Summary Background Data: Current data on the effect of an extended interval between radiochemotherapy (RCT) and resection for rectal cancer on the rate of complete pathological response (pCR=ypT0N0) is controversial. Furthermore, its effect on oncological outcomes is unknown. Methods: The GRECCAR-6 trial was a phase III, multicenter, randomized, open-label, parallel-group, controlled trial. Patients with cT3/T4 or TxN+ tumors of the mid or lower rectum who had received RCT (45-50 Gy with 5-fluorouracil or capecitabine) were included and randomized into a 7- or 11-week waiting period. Primary endpoint was the pCR rate. Secondary endpoints were 3-year overall (OS), disease-free survival (DFS), and recurrence rates. Results: A total of 265 patients from 24 participating centers were enrolled. A total of 253 patients underwent a mesorectal excision. Overall pCR rate was 17% (43/253). Mean follow-up from surgical resection was 32 ± 8 months. Twenty-four deaths occurred with an 89% OS at 3 years. DFS was 68.7% at 3 years (75 recurrences). Three-year local and distant recurrences were 7.9% and 23.8%, respectively. The randomization group had no impact on the 3- year OS (P = 0.8868) or DFS (P = 0.9409). Distant (P = 0.7432) and local (P = 0.3944) recurrences were also not influenced by the waiting period. DFS was independently influenced by 3 factors: circumferential radial margin (CRM) ≤1 mm [hazard ratio (HR) = 2.03; 95% confidence interval (CI), 1.17-3.51], ypT3-T4 (HR = 2.69; 95% CI, 1.19-6.08) and positive lymph nodes (HR = 3.62; 95% CI, 1.89-6.91). Conclusion: Extending the waiting period by 4 weeks following RCT has no influence on the oncological outcomes of T3/T4 rectal cancers. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

100. Translocation t(1;6)(p35.3;p25.2): a new recurrent aberration in ‘unmutated’ B-CLL

Author

Anne Hagemeijer, A. Van Hoof, Arnold Criel, K Kargar Samani, Iwona Wlodarska, Lucienne Michaux, Michel Stul, Marie Maerevoet, S. Marichal, Hilde Demuynck, Katrina Rack, Augustin Ferrant, Peter Marynen, and P. Mineur

Subjects
Cancer Research, medicine.medical_specialty, Pathology, Hematology, medicine.diagnostic_test, Chronic lymphocytic leukemia, Breakpoint, Chromosomal translocation, Karyotype, Biology, medicine.disease, Leukemia, Lymphocytic, Chronic, B-Cell, Translocation, Genetic, Lymphoma, Oncology, Chromosomes, Human, Pair 1, Karyotyping, Internal medicine, medicine, Humans, Chromosomes, Human, Pair 6, Trisomy, In Situ Hybridization, Fluorescence, Fluorescence in situ hybridization
Abstract

Although reciprocal chromosomal translocations are not typical for B-cell chronic lymphocytic leukemia (B-CLL), we identified the novel t(1;6)(p35.3;p25.2) in eight patients with this disorder. Interestingly, all cases showed lack of somatically mutated IgV(H). Clinical, morphological, immunologic, and genetic features of these patients are described. Briefly, the age ranged from 33 to 81 years (median: 62.5 years) and the sex ratio was 6M:2F. Most of the patients (6/8) presented with advanced clinical stage. Therapy was required in seven cases. After a median follow-up of 28 months, five patients are alive and three died from disease evolution. Three cases developed transformation into diffuse large B-cell lymphoma. Translocation t(1;6) was found as the primary karyotypic abnormality in three patients. Additional chromosomal aberrations included changes frequently found in unmutated B-CLL, that is, del(11)(q), trisomy 12 and 17p aberrations. Fluorescence in situ hybridization analysis performed in seven cases allowed us to map the t(1;6) breakpoints to the 1p35.3 and 6p25.2 chromosomal bands, respectively. The latter breakpoint was located in the genomic region coding for MUM1/IRF4, one of the key regulators of lymphocyte development and proliferation, suggesting involvement of this gene in the t(1;6). Molecular characterization of the t(1;6)(p35.3;p25.2), exclusively found in unmutated subtype of B-CLL, is in progress.

Published
2004

Catalog

Books, media, physical & digital resources
See catalog results